Navigation Links
BioXcel Launches Its Flagship Product, PharmGPS™

Branford, CT (PRWEB) April 22, 2013

BioXcel Corporation, coinciding with the BIO International 2013 Convention in Chicago, announced the launch of PharmGPS™, a “first-in-class,” dynamic analytics platform with customizable apps, built to address complex investment decisions across the biopharmaceutical industry stakeholder value-chain.

“Decision making and knowledge management paradigms are fragmented and becoming increasingly complex with the explosion of data and a rapidly evolving healthcare ecosystem,” said Dr. Vimal Mehta, BioXcel’s Chairman. “PharmGPS™ provides an innovative solution to revolutionize decision making with a unified platform for actionable decisions thereby optimizing investments and enhancing the probability of success.

PharmGPS™ is a disease-area focused, analytics engine encompassing all major and specialty therapeutic areas. Using a patient-centric approach, PharmGPS™ assesses each disease indication for the best window of commercial opportunity, dynamic probability of technical and regulatory success, forecasting, and scenario analysis. This applies to both in-market and pipeline drugs, satisfying the future standard of care in each disease indication/segment. “BioXcel’s long-term commitment to developing PharmGPSTM has been supported by multiple clients working to meet patient needs,” said Dr. Krishnan Nandabalan, BioXcel’s President & CEO. “We are vigorously expanding current indications and commercializing this exciting new product to a wide biopharmaceutical audience.”

The platform is built on several years’ experience, deep domain expertise, commercially validated frameworks, and proprietary processes for generating insights and recommendations. The analytics engine operates on dynamic specialized data sets, each structured by experts from medical, clinical, scientific, commercial, and intellectual property disciplines. It also allows stakeholders to leverage internal organic and confidential data via customized, downloadable “apps” backed by BioXcel’s expert consulting and technology services. Multiple teams’ decision-journeys will be empowered by PharmGPS™, ranging from strategy, business development/licensing, research & development, and commercial development/branding.

About BioXcel
BioXcel Corporation is a leading, analytics-based consulting company that provides 360° decision support solutions through its expert services and analytics enabled platform, PharmGPS™. BioXcel has grown steadily as an analytics and consulting partner during the last seven years, serving the biopharmaceutical industry exclusively.
BioXcel Corporation is headquartered in Branford, CT, USA.

Dr. Krishnan Nandabalan
780 East Main Street
Branford, CT 06405
Phone: 203 433 4086
Mobile: 203 606 3000
Email: knandabalan(at)bioxcel(dot)com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
4. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
5. Neogen Launches Fully Quantitative Lateral Flow Test for DON
6. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
7. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
8. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
9. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
10. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
11. ERT Launches New Website to Support Significant Commercial Growth
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
(Date:11/24/2015)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR ... and commercialization of first-in-class therapeutics, today announced that ... to present at the 2015 Piper Jaffray Healthcare Conference ... The Lotte New York Palace Hotel in ... --> . --> ...
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
Breaking Biology Technology:
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... in modern authentication and a founding member of the ... its latest version of the Nok Nok™ S3 Authentication ... standards-based authentication that supports existing and emerging methods of ... ideal for organizations deploying customer-facing applications that require Internet ...
Breaking Biology News(10 mins):